{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T14:21:21Z","timestamp":1783174881991,"version":"3.54.6"},"publisher-location":"New York, NY","reference-count":48,"publisher":"Springer US","isbn-type":[{"value":"9781071652480","type":"print"},{"value":"9781071652497","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5249-7_5","type":"book-chapter","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:53:41Z","timestamp":1783173221000},"page":"75-99","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Yeast Display of Single-Chain Fc Fragments with Modulated Binding of Effector Molecules"],"prefix":"10.1007","author":[{"given":"Katharina","family":"Stadlbauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Wick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Gobl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Wallner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika de Sousa","family":"Linhares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Stritzker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana","family":"Wozniak-Knopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,5]]},"reference":[{"key":"5_CR1","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.1074\/jbc.M009483200","volume":"276","author":"RL Shields","year":"2001","unstructured":"Shields RL, Namenuk AK, Hong K et al. (2001) High resolution mapping of the binding site on human IgG1 for Fc\u03b3RI, Fc\u03b3RII, Fc\u03b3RIII, and FcRn and design of IgG1 variants with improved binding to the Fc\u03b3R. J Biol Chem 276:6591\u20136604. https:\/\/doi.org\/10.1074\/jbc.M009483200","journal-title":"J Biol Chem"},{"key":"5_CR2","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","volume":"113","author":"P Bruhns","year":"2009","unstructured":"Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Da\u00ebron M (2009) Specificity and affinity of human Fc\u03b3 receptors and their polymorphic variants for human IgG subclasses. Blood 113:3716\u20133725. https:\/\/doi.org\/10.1182\/blood-2008-09-179754","journal-title":"Blood"},{"key":"5_CR3","doi-asserted-by":"publisher","first-page":"8882","DOI":"10.1158\/0008-5472.CAN-07-0696","volume":"67","author":"JB Stavenhagen","year":"2007","unstructured":"Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Johnson S, Bonvini E, Koenig S (2007) Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fc\u03b3 receptors. Cancer Res 67:8882\u20138890. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-0696","journal-title":"Cancer Res"},{"key":"5_CR4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s40265-021-01485-2","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A (2021) Margetuximab: first approval. Drugs 81:599\u2013604. https:\/\/doi.org\/10.1007\/s40265-021-01485-2","journal-title":"Drugs"},{"key":"5_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19420862.2022.2123299","volume":"14","author":"I Wilkinson","year":"2022","unstructured":"Wilkinson I, Hale G (2022) Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names. Mabs 14:1\u201315. https:\/\/doi.org\/10.1080\/19420862.2022.2123299","journal-title":"Mabs"},{"key":"5_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19420862.2024.2402701","volume":"16","author":"G Hale","year":"2024","unstructured":"Hale G, De Vos J, Davy AD, Sandra K, Wilkinson I (2024) Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors. Mabs 16:1\u201315. https:\/\/doi.org\/10.1080\/19420862.2024.2402701","journal-title":"Mabs"},{"key":"5_CR7","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1073\/pnas.0908590107","volume":"107","author":"ST Jung","year":"2010","unstructured":"Jung ST, Reddy ST, Kang TH, Borrok MJ, Sandlie I, Tucker PW, Georgiou G (2010) Aglycosylated IgG variants expressed in bacteria that selectively bind Fc\u03b3RI potentiate tumor cell killing by monocyte-dendritic cells. Proc Natl Acad Sci U S A 107:604\u2013609. https:\/\/doi.org\/10.1073\/pnas.0908590107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5_CR8","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1007\/s12257-013-0432-z","volume":"19","author":"ST Jung","year":"2014","unstructured":"Jung ST, Kang TH, Kim Dil (2014) Engineering an aglycosylated Fc variant for enhanced Fc\u03b3RI engagement and pH-dependent human FcRn binding. Biotechnol Bioprocess Eng 19:780\u2013789. https:\/\/doi.org\/10.1007\/s12257-013-0432-z","journal-title":"Biotechnol Bioprocess Eng"},{"key":"5_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1080\/19420862.2017.1402995","volume":"10","author":"M Jo","year":"2018","unstructured":"Jo M, Kwon HS, Lee KH, Lee JC, Jung ST (2018) Engineered aglycosylated full-length IgG Fc variants exhibiting improved Fc\u03b3RIIIa binding and tumor cell clearance. Mabs 10:278\u2013289. https:\/\/doi.org\/10.1080\/19420862.2017.1402995","journal-title":"Mabs"},{"key":"5_CR10","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1021\/cb300455f","volume":"8","author":"ST Jung","year":"2013","unstructured":"Jung ST, Kelton W, Kang TH, Ng DTW, Andersen JT, Sandlie I, Sarkar CA, Georgiou G (2013) Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated igg displaying high Fc\u03b3RIIa affinity and selectivity. ACS Chem Biol 8:368\u2013375. https:\/\/doi.org\/10.1021\/cb300455f","journal-title":"ACS Chem Biol"},{"key":"5_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","volume":"584","author":"R Shi","year":"2020","unstructured":"Shi R, Shan C, Duan X et al. (2020) A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584:120\u2013124. https:\/\/doi.org\/10.1038\/s41586-020-2381-y","journal-title":"Nature"},{"key":"5_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.abl8124","volume":"14","author":"YM Loo","year":"2022","unstructured":"Loo YM, McTamney PM, Arends RH et al. (2022) The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Sci Transl Med 14:1\u201314. https:\/\/doi.org\/10.1126\/scitranslmed.abl8124","journal-title":"Sci Transl Med"},{"key":"5_CR13","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni.3770","volume":"18","author":"CH Lee","year":"2017","unstructured":"Lee CH, Romain G, Yan W et al. (2017) IgG Fc domains that bind C1q but not effector Fc3 receptors delineate the importance of complement-mediated effector functions. Nat Immunol 18:889\u2013898. https:\/\/doi.org\/10.1038\/ni.3770","journal-title":"Nat Immunol"},{"key":"5_CR14","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/PRO.3598","volume":"28","author":"S Saito","year":"2019","unstructured":"Saito S, Namisaki H, Hiraishi K, Takahashi N, Iida S (2019) A stable engineered human IgG3 antibody with decreased aggregation during antibody expression and low pH stress. Protein Sci 28:900\u2013909. https:\/\/doi.org\/10.1002\/PRO.3598","journal-title":"Protein Sci"},{"key":"5_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19420862.2021.1882028","volume":"13","author":"TH Chu","year":"2021","unstructured":"Chu TH, Patz EF, Ackerman ME (2021) Coming together at the hinges: therapeutic prospects of IgG3. Mabs 13:1\u201315. https:\/\/doi.org\/10.1080\/19420862.2021.1882028","journal-title":"Mabs"},{"key":"5_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40265-022-01829-6","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ (2023) Nirsevimab: first approval. Drugs 83:181\u2013187. https:\/\/doi.org\/10.1007\/s40265-022-01829-6","journal-title":"Drugs"},{"key":"5_CR17","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.4049\/jimmunol.169.9.5171","volume":"169","author":"WFD Acqua","year":"2002","unstructured":"Acqua WFD, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S (2002) Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 169:5171\u20135180. https:\/\/doi.org\/10.4049\/jimmunol.169.9.5171","journal-title":"J Immunol"},{"key":"5_CR18","doi-asserted-by":"publisher","first-page":"23514","DOI":"10.1074\/jbc.M604292200","volume":"281","author":"WF Dall\u2019Acqua","year":"2006","unstructured":"Dall\u2019Acqua WF, Kiener PA, Wu H (2006) Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281:23514\u201323524. https:\/\/doi.org\/10.1074\/jbc.M604292200","journal-title":"J Biol Chem"},{"issue":"10","key":"5_CR19","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/nbt1143","volume":"23","author":"C Vaccaro","year":"2005","unstructured":"Vaccaro C, Zhou J, Ober RJ, Ward ES (2005) Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 23(10):1283\u20131288. https:\/\/doi.org\/10.1038\/nbt1143","journal-title":"Nat Biotechnol"},{"key":"5_CR20","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T et al. (2018) Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest 128:4372\u20134386. https:\/\/doi.org\/10.1172\/JCI97911","journal-title":"J Clin Invest"},{"key":"5_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/S40265-022-01678-3","volume":"82","author":"YA Heo","year":"2022","unstructured":"Heo YA (2022) Efgartigimod: first approval. Drugs 82:341\u2013348. https:\/\/doi.org\/10.1007\/S40265-022-01678-3","journal-title":"Drugs"},{"key":"5_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-021-02565-5","volume":"4","author":"L Shan","year":"2021","unstructured":"Shan L, Dyk NVan, Haskins N et al. (2021) In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance. Commun Biol 4:1\u201311. https:\/\/doi.org\/10.1038\/s42003-021-02565-5","journal-title":"Commun Biol"},{"key":"5_CR23","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI (2019) Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov 18:585\u2013608. https:\/\/doi.org\/10.1038\/s41573-019-0028-1","journal-title":"Nat Rev Drug Discov"},{"key":"5_CR24","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/1380-2933(96)80685-3","volume":"9","author":"JBB Ridgway","year":"1996","unstructured":"Ridgway JBB, Presta LG, Carter P (1996) \u201cKnobs-into-holes\u201d engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 9:617\u2013621. https:\/\/doi.org\/10.1016\/1380-2933(96)80685-3","journal-title":"Protein Eng"},{"key":"5_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1006\/JMBI.1997.1116","volume":"270","author":"S Atwell","year":"1997","unstructured":"Atwell S, Ridgway JBB, Wells JA, Carter P (1997) Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol 270:26\u201335. https:\/\/doi.org\/10.1006\/JMBI.1997.1116","journal-title":"J Mol Biol"},{"key":"5_CR26","doi-asserted-by":"publisher","first-page":"e0145349","DOI":"10.1371\/JOURNAL.PONE.0145349","volume":"10","author":"HJ Choi","year":"2015","unstructured":"Choi HJ, Kim YJ, Choi DK, Kim YS (2015) Engineering of immunoglobulin Fc heterodimers using yeast surface-displayed combinatorial Fc library screening. PLoS One 10:e0145349. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0145349","journal-title":"PLoS One"},{"key":"5_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/978-1-0716-3279-6_9","volume":"2681","author":"F Benedetti","year":"2023","unstructured":"Benedetti F, Stadlmayr G, Stadlbauer K, R\u00fcker F, Wozniak-Knopp G (2023) Selection of high-affinity heterodimeric antigen-binding Fc fragments from a large yeast display library. Methods Mol Biol 2681:131\u2013159. https:\/\/doi.org\/10.1007\/978-1-0716-3279-6_9","journal-title":"Methods Mol Biol"},{"key":"5_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-40681-4","volume":"14","author":"KS Chew","year":"2023","unstructured":"Chew KS, Wells RC, Moshkforoush A et al. (2023) CD98hc is a target for brain delivery of biotherapeutics. Nat Commun 14:1\u201317. https:\/\/doi.org\/10.1038\/s41467-023-40681-4","journal-title":"Nat Commun"},{"key":"5_CR29","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1073\/pnas.0508123103","volume":"103","author":"GA Lazar","year":"2006","unstructured":"Lazar GA, Dang W, Karki S et al. (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 103:4005\u20134010. https:\/\/doi.org\/10.1073\/pnas.0508123103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.4161\/MABS.23452","volume":"5","author":"F Mimoto","year":"2013","unstructured":"Mimoto F, Igawa T, Kuramochi T, Katada H, Kadono S, Kamikawa T, Shida-Kawazoe M, Hattori K (2013) Novel asymmetrically engineered antibody Fc variant with superior Fc\u03b3R binding affinity and specificity compared with afucosylated Fc variant. Mabs 5:229\u2013236. https:\/\/doi.org\/10.4161\/MABS.23452","journal-title":"Mabs"},{"key":"5_CR31","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40265-024-02070-z","volume":"84","author":"S Dhillon","year":"2024","unstructured":"Dhillon S (2024) Tarlatamab: first approval. Drugs 84:995\u20131003. https:\/\/doi.org\/10.1007\/s40265-024-02070-z","journal-title":"Drugs"},{"key":"5_CR32","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/JNC.15768","volume":"165","author":"JI Morrison","year":"2023","unstructured":"Morrison JI, Metzendorf NG, Rofo F, Petrovic A, Hultqvist G (2023) A single-chain fragment constant design enables easy production of a monovalent blood\u2013brain barrier transporter and provides an improved brain uptake at elevated doses. J Neurochem 165:413\u2013425. https:\/\/doi.org\/10.1111\/JNC.15768","journal-title":"J Neurochem"},{"key":"5_CR33","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/J.CHEMBIOL.2024.07.004","volume":"31","author":"RC Oslund","year":"2024","unstructured":"Oslund RC, Holland PM, Lesley SA, Fadeyi OO (2024) Therapeutic potential of cis-targeting bispecific antibodies. Cell Chem Biol 31:1473\u20131489. https:\/\/doi.org\/10.1016\/J.CHEMBIOL.2024.07.004","journal-title":"Cell Chem Biol"},{"key":"5_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep40098","volume":"7","author":"Y Mazor","year":"2017","unstructured":"Mazor Y, Sachsenmeier KF, Yang C, Hansen A, Filderman J, Mulgrew K, Wu H, Dall\u2019Acqua WF (2017) Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. Sci Rep 7:1\u201311. https:\/\/doi.org\/10.1038\/srep40098","journal-title":"Sci Rep"},{"key":"5_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/J.BIOMATERIALS.2016.11.051","volume":"117","author":"L Zhou","year":"2017","unstructured":"Zhou L, Wang HY, Tong S, Okamoto CT, Shen WC, Zaro JL (2017) Single chain Fc-dimer-human growth hormone fusion protein for improved drug delivery. Biomaterials 117:24\u201331. https:\/\/doi.org\/10.1016\/J.BIOMATERIALS.2016.11.051","journal-title":"Biomaterials"},{"key":"5_CR36","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2165\/00063030-200620030-00002","volume":"20","author":"JA Dumont","year":"2006","unstructured":"Dumont JA, Low SC, Peters RT, Bitonti AJ (2006) Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs 20:151\u2013160. https:\/\/doi.org\/10.2165\/00063030-200620030-00002","journal-title":"BioDrugs"},{"key":"5_CR37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/14712598.2024.2436094","volume":"25","author":"U Binder","year":"2024","unstructured":"Binder U, Skerra A (2024) Strategies for extending the half-life of biotherapeutics: successes and complications. Expert Opin Biol Ther 25:93\u2013118. https:\/\/doi.org\/10.1080\/14712598.2024.2436094","journal-title":"Expert Opin Biol Ther"},{"key":"5_CR38","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/PROTEIN\/11.5.405","volume":"11","author":"F Hennecke","year":"1998","unstructured":"Hennecke F, Krebber C, Pl\u00fcckthun A (1998) Non-repetitive single-chain Fv linkers selected by selectively infective phage (SIP) technology. Protein Eng Des Sel 11:405\u2013410. https:\/\/doi.org\/10.1093\/PROTEIN\/11.5.405","journal-title":"Protein Eng Des Sel"},{"key":"5_CR39","doi-asserted-by":"publisher","first-page":"308","DOI":"10.7150\/thno.17155","volume":"7","author":"G Hultqvist","year":"2017","unstructured":"Hultqvist G, Syv\u00e4nen S, Fang XT, Lannfelt L, Sehlin D (2017) Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor. Theranostics 7:308\u2013318. https:\/\/doi.org\/10.7150\/thno.17155","journal-title":"Theranostics"},{"key":"5_CR40","doi-asserted-by":"publisher","first-page":"W296","DOI":"10.1093\/NAR\/GKY427","volume":"46","author":"A Waterhouse","year":"2018","unstructured":"Waterhouse A, Bertoni M, Bienert S et al. (2018) SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res 46:W296\u2013W303. https:\/\/doi.org\/10.1093\/NAR\/GKY427","journal-title":"Nucleic Acids Res"},{"issue":"8016","key":"5_CR41","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson J, Adler J, Dunger J et al. (2024) Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630(8016):493\u2013500. https:\/\/doi.org\/10.1038\/s41586-024-07487-w","journal-title":"Nature"},{"key":"5_CR42","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1021\/CT900549R","volume":"6","author":"E Lindahl","year":"2010","unstructured":"Lindahl E, Bjelkmar P, Larsson P, Cuendet MA, Hess B (2010) Implementation of the CHARMM force field in GROMACS: analysis of protein stability effects from correction maps, virtual interaction sites, and water models. J Chem Theory Comput 6:459\u2013466. https:\/\/doi.org\/10.1021\/CT900549R","journal-title":"J Chem Theory Comput"},{"key":"5_CR43","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nbt0697-553","volume":"15","author":"ET Boder","year":"1997","unstructured":"Boder ET, Wittrup KD (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15:553\u2013557. https:\/\/doi.org\/10.1038\/nbt0697-553","journal-title":"Nat Biotechnol"},{"key":"5_CR44","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nprot.2006.94","volume":"1","author":"G Chao","year":"2006","unstructured":"Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD (2006) Isolating and engineering human antibodies using yeast surface display. Nat Protoc 1:755\u2013768. https:\/\/doi.org\/10.1038\/nprot.2006.94","journal-title":"Nat Protoc"},{"key":"5_CR45","doi-asserted-by":"publisher","first-page":"134","DOI":"10.2144\/99261RR02","volume":"26","author":"CK Raymond","year":"1999","unstructured":"Raymond CK, Pownder TA, Sexson SL (1999) General method for plasmid construction using homologous recombination. Biotechniques 26:134\u2013141. https:\/\/doi.org\/10.2144\/99261RR02","journal-title":"Biotechniques"},{"key":"5_CR46","doi-asserted-by":"publisher","first-page":"20404","DOI":"10.1073\/pnas.0811011106","volume":"105","author":"DG Gibson","year":"2008","unstructured":"Gibson DG, Benders GA, Axelrod KC, Zaveri J, Algire MA, Moodie M, Montague MG, Venter JC, Smith HO, Hutchison CA (2008) One-step assembly in yeast of 25 overlapping DNA fragments to form a complete synthetic Mycoplasma genitalium genome. Proc Natl Acad Sci U S A 105:20404\u201320409. https:\/\/doi.org\/10.1073\/pnas.0811011106","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5_CR47","doi-asserted-by":"publisher","first-page":"11048","DOI":"10.1073\/pnas.1810566115","volume":"115","author":"DA Knorr","year":"2018","unstructured":"Knorr DA, Dahan R, Ravetch JV (2018) Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity. Proc Natl Acad Sci USA 115:11048\u201311053. https:\/\/doi.org\/10.1073\/pnas.1810566115","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5_CR48","doi-asserted-by":"publisher","first-page":"12994","DOI":"10.1074\/jbc.M117.795047","volume":"292","author":"PA Blundell","year":"2017","unstructured":"Blundell PA, Le NPL, Allen J, Watanabe Y, Pleass RJ (2017) Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors. J Biol Chem 292:12994\u201313007. https:\/\/doi.org\/10.1074\/jbc.M117.795047","journal-title":"J Biol Chem"}],"container-title":["Methods in Molecular Biology","Biomolecular Display Technologies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5249-7_5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:53:42Z","timestamp":1783173222000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5249-7_5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071652480","9781071652497"],"references-count":48,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5249-7_5","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"5 July 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}